- Conditions
- Hodgkin Lymphoma
- Interventions
- Brentuximab Vedotin, Adriamycin, vinblastine, and dacarbazine
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 4
- States / cities
- Tampa, Florida • Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1225–1248
of 20,701
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Lutetium Lu 177 Vipivotide Tetraxetan, Cell-free Circulating Tumor DNA Assay, Computed Tomography, Docetaxel, PSMA PET Scan, Single Photon Tomography and Computed Tomography Scan, Biospecimen Collection
- Drug · Procedure
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Sickle Cell Disease
- Interventions
- Single blood transfusion, Standard care
- Biological · Behavioral
- Lead sponsor
- Carelon Research
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 237 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 24
- States / cities
- Oakland, California • Wilmington, Delaware • Washington D.C., District of Columbia + 14 more
- Conditions
- Venous Thromboembolism
- Interventions
- Not listed
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 21,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory Hairy Cell Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Testicular Lymphoma, Waldenström Macroglobulinemia
- Interventions
- ipilimumab, laboratory biomarker analysis
- Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Melanoma (Skin)
- Interventions
- carboplatin, paclitaxel albumin-stabilized nanoparticle formulation
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 156
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Aurora, Illinois + 98 more
- Conditions
- Healthy
- Interventions
- Glucose100, Glucose50, Glucose42, Oral Glucose Tolerance Test
- Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Open Posterior Thoracolumbar Spinal Fusion Procedure
- Interventions
- Tranexamic Acid Injectable Product (1000 mg intravenous bolus), Vitamin C 250 MG Oral Tablet, Tranexamic Acid 650Mg Tablet
- Drug
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 604 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Leukemia
- Interventions
- filgrastim, cladribine, idarubicin
- Biological · Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2007
- U.S. locations
- 206
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myelodysplastic Syndromes, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, B-Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia, Lymphoblastic Lymphoma, Burkitt's Lymphoma, Non-Hodgkin's Lymphoma, Multiple Myeloma, Myeloproliferative Syndromes, Hematological Diseases
- Interventions
- Allopurinol, Fludarabine, Cyclophosphamide, ATG, TBI, Tacrolimus, MMF, Peripheral Blood Stem Cells, Related or Unrelated Bone Marrow Cells
- Drug · Radiation · Biological
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 75 Years
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Type 2 Diabetes, Cardiovascular Diseases
- Interventions
- Pistachio, Usual care
- Drug · Other
- Lead sponsor
- Penn State University
- Other
- Eligibility
- 30 Years to 65 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- University Park, Pennsylvania
- Conditions
- Non-Hodgkin Lymphoma
- Interventions
- Biospecimen Collection, Computed Tomography, Positron Emission Tomography, Siltuximab
- Procedure · Biological
- Lead sponsor
- Timothy Voorhees
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Chronic Pain, Hypertension, Implanted Stimulation Electrodes
- Interventions
- Diagnostic Tests
- Diagnostic Test
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 30 Years to 89 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 2
- States / cities
- Fairway, Kansas • Kansas City, Kansas
- Conditions
- Neurodevelopmental Abnormality
- Interventions
- Umbilical Cord Milking, Early Cord Clamping
- Procedure
- Lead sponsor
- Sharp HealthCare
- Other
- Eligibility
- 22 Months to 26 Months
- Enrollment
- 1,207 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 7
- States / cities
- Davis, California • Loma Linda, California • San Diego, California + 3 more
- Conditions
- Healthy
- Interventions
- AMD3100 (Mozobil plerixafor)
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2012
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Achilles Injuries Tendon
- Interventions
- Standard of Care Physical Therapy, Blood flow restriction
- Other
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Pharmacokinetics
- Interventions
- 1 gram of a protein hydrolysate, 2 grams of a protein hydrolysate, 4 grams of a protein hydrolysate, 8 grams of a protein hydrolysate
- Dietary Supplement
- Lead sponsor
- Natural Immune Systems Inc
- Other
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Klamath Falls, Oregon
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Undifferentiated Leukemia, Allogeneic Hematopoietic Stem Cell Transplant Recipient, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blastic Plasmacytoid Dendritic Cell Neoplasm, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Donor, Lymphoblastic Lymphoma, Myelodysplastic Syndrome With Excess Blasts, Myelodysplastic Syndrome With Excess Blasts-1, Myelodysplastic Syndrome With Excess Blasts-2, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Methotrexate, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Tacrolimus, Thiotepa, Total-Body Irradiation
- Procedure · Drug · Other + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 60 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2025
- U.S. locations
- 2
- States / cities
- Pittsburgh, Pennsylvania • Seattle, Washington
- Conditions
- Renal Cell Carcinoma
- Interventions
- Nivolumab
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 197 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 39
- States / cities
- Phoenix, Arizona • Bakersfield, California • Fullerton, California + 35 more
- Conditions
- Leukemia, Not Otherwise Specified, Leukemia, Other
- Interventions
- Cyclophosphamide, Specimen collection
- Drug · Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2035
- U.S. locations
- 1
- States / cities
- Charlotte, North Carolina
- Conditions
- Carcinoma, Small Cell Lung
- Interventions
- irinotecan, carboplatin, bevacizumab
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 4
- States / cities
- Fort Myers, Florida • Cincinnati, Ohio • Chattanooga, Tennessee + 1 more
- Conditions
- Aids-related Malignancies, Lymphoma, Precancerous Condition, Sarcoma
- Interventions
- polymerase chain reaction, cytology specimen collection procedure, histological technique, colposcopic biopsy
- Genetic · Other · Procedure
- Lead sponsor
- AIDS Malignancy Consortium
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2017
- U.S. locations
- 10
- States / cities
- La Jolla, California • Los Angeles, California • San Francisco, California + 5 more
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- PDS Implant With Ranibizumab 100 mg/ml, LUCENTIS (Ranibizumab Injection)
- Device · Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 40
- States / cities
- Mesa, Arizona • Bakersfield, California • Huntington Beach, California + 36 more
- Conditions
- Patients Requiring Endotracheal Intubation
- Interventions
- tracheal lavages
- Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- St Louis, Missouri